| Meta-analysis of conestat alfa studies | ||
| Meta-analysis of conestat alfa studies | ||
Oct 27 2023 |
et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1255292 | Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial |
| 238% higher mortality (p=0.26), 286% higher ventilation (p=0.26), 141% higher ICU admission (p=0.32), and 117% lower hospital discharge (p=0.12). RCT 84 hospitalized COVID-19 patients showing higher mortality with conestat alfa (recombinant C1 inhibitor), without reaching statistical significance. | ||
Dec 1 2021 |
et al., NCT04530136 | Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US |
| 78% lower mortality (p=0.29), 87% lower ventilation (p=0.08), 46% lower progression (p=0.07), and 52% shorter hospitalization (p=0.06). RCT 38 hospitalized COVID-19 patients showing non-significant improvements with conestat alfa. Results of this manufacturer RCT are notably better than the non-manufacturer RCT [Urwyler]. | ||
